Want to see STLN full AI Analyst Report?
STLN Stock Chart & Stats
$5.19
$0.21(4.22%)
At close: 4:00 PM EDT
$5.19
$0.21(4.22%)
Day’s Range― - ―
52-Week Range$2.32 - $6.67
Previous Close$5.21
VolumeN/A
Average Volume (3M)1.95M
Market Cap
$485.92M
Enterprise Value$387.11
Total Cash (Recent Filing)$30.28M
Total Debt (Recent Filing)$104.86M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Aug 06, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding99,982,930
10 Day Avg. Volume1,978,047
30 Day Avg. Volume1,952,546
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)-209.23
Price to Sales (P/S)6.54
P/FCF Ratio-118.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.50Price Target Upside63.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.14
Revenue Forecast (FY)$651.84M
Bulls Say, Bears Say
Bulls Say
Top-line Growth (41% YoY)Sustained high revenue growth reflects successful market expansion and increasing scale across services. Durable top-line momentum supports operating leverage, funds continued clinic openings and technology investments, and reduces per-unit SG&A, strengthening medium-term profitability prospects.
Capitation/value-based ExpansionRapid shift toward capitated contracts increases recurring, predictable revenue and aligns incentives with payers to manage total cost of care. As delegated MA lives scale, capitation can stabilize cash flow, improve long-run revenue visibility and support margin improvement if utilization is managed.
Specialty Pharmacy ScaleLarge and fast-growing specialty pharmacy provides a durable ancillary revenue stream with scalable unit economics. Higher fill volumes and pharmacy gross profit contribute recurring cash flow potential and vertical integration benefits that can enhance margins and patient capture over the medium term.
Bears Say
Negative Stockholders' EquityAccumulated losses producing negative equity constrain financial flexibility and increase solvency and covenant sensitivity. This structural capital weakness raises the probability of dilutive financings or restrictive covenant outcomes if operating improvements stall, limiting strategic optionality.
Persistent Negative Cash FlowContinued negative operating and free cash flow means the business is not yet self-funding growth, requiring ongoing external capital or debt. Even with improvements, sustained cash burn heightens refinancing and liquidity risk over the medium term, stressing capital structure durability.
Margin Pressure From Delegated ContractsThe shift to delegated/value contracts and lower pharmacy revenue per fill exerts structural pressure on gross margins. As lower-margin capitated business scales, sustaining overall profitability requires continued operating leverage and ancillary capture; failure to do so could compress long-term margins.
STLN FAQ
What was Starling Oncology Institute’s price range in the past 12 months?
Starling Oncology Institute lowest stock price was $2.32 and its highest was $6.67 in the past 12 months.
What is Starling Oncology Institute’s market cap?
Starling Oncology Institute’s market cap is $485.92M.
When is Starling Oncology Institute’s upcoming earnings report date?
Starling Oncology Institute’s upcoming earnings report date is Aug 06, 2026 which is today.
How were Starling Oncology Institute’s earnings last quarter?
Currently, no data Available
Is Starling Oncology Institute overvalued?
According to Wall Street analysts Starling Oncology Institute’s price is currently Undervalued.
Does Starling Oncology Institute pay dividends?
Starling Oncology Institute does not currently pay dividends.
What is Starling Oncology Institute’s EPS estimate?
Starling Oncology Institute’s EPS estimate is -0.06.
How many shares outstanding does Starling Oncology Institute have?
Starling Oncology Institute has 99,982,930 shares outstanding.
What happened to Starling Oncology Institute’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Starling Oncology Institute?
Currently, no hedge funds are holding shares in STLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Starling Oncology Institute Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (63.78% Upside)
$8.50 (63.78% Upside)
Blogger Sentiment
Bullish
STLN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 217.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $371.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 14.3%
Last 30 Days ▲ 14.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.58%
Trailing 12-Months
Company Description
Starling Oncology Institute
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
STLN Stock 12 Month Forecast
Average Price Target
$8.50
▲(63.78% Upside)
Technical Analysis
Ownership Overview
24.32% Insiders
7.06% Mutual Funds
0.39% Other Institutional Investors
59.29% Public Companies and
Individual Investors